This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01088711
First received: March 16, 2010
Last updated: June 1, 2017
Last verified: June 2017
March 16, 2010
June 1, 2017
March 11, 2010
May 11, 2010   (Final data collection date for primary outcome measure)
  • Number of Participants Experiencing an Adverse Event (AE) [ Time Frame: Up to Day 36 ]
  • Number of Participants Withdrawing From Study Therapy Due to an AE [ Time Frame: Up to Day 22 ]
Safety and tolerability of MK3102 measured by number of clinical and laboratory adverse experiences [ Time Frame: through 14 days post last dose ]
Complete list of historical versions of study NCT01088711 on ClinicalTrials.gov Archive Site
  • Percent Inhibition of Dipeptidyl Peptidase-4 (DPP-4) After Day 15 [ Time Frame: 168 hours post-dose on Day 15 ]
    Percent DPP-4 inhibition at 168 hours after the Day 15 dose (from baseline [pre-dose on Day 1]) was compared in healthy and T2D participants receiving omarigliptin or placebo.
  • Percent Inhibition of DPP-4 After Day 22 [ Time Frame: 168 hours post dose on Day 22 ]
    Percent DPP-4 inhibition at 168 hours after the Day 22 dose (from baseline [pre-dose on Day 1]) was compared in healthy and T2D participants receiving omarigliptin or placebo.
  • WAA Active Glucagon-like Peptide-1 (GLP-1) Concentration [ Time Frame: Through 4 hours post dose on Day 21 ]
    Weighted average augmentation (WAA) active GLP-1 concentration was based on the 0.25, 0.5, 1, 2, and 4 hour timepoints. WAA was calculated as area under the curve (AUC) for the 4-hr post-dose time period (AUC0-4 hrs); this AUC was then divided by the time interval of 4 hours to obtain WAA. Log scale data were then back-transformed to obtain LS means.
  • WAA Total GLP-1 Concentration [ Time Frame: Through 4 hours post dose on Day 21 ]
    WAA total GLP-1 concentration was based on the 0.25, 0.5, 1, 2, and 4 hour timepoints. WAA was calculated as AUC0-4 hrs; this AUC was then divided by the time interval of 4 hours to obtain WAA. Log scale data were then back-transformed to obtain LS means.
  • Plasma Glucose Concentration [ Time Frame: Through 4 hours post dose on Day 21 ]
    Post-prandial glucose concentration is presented as a weighted average of the 0.25, 0.5, 1, 2, and 4 hour post-dose time points. Glucose concentration was calculated as area under the curve (AUC) for the 4-hr post-dose time period (AUC0-4 hrs); this AUC was then divided by the time interval of 4 hours to obtain weighted average glucose concentration. Log scale data were then back-transformed to obtain LS means.
  • percent inhibition of target enzyme [ Time Frame: 168 hours post last dose ]
  • Active GLP-1 concentrations [ Time Frame: Through 4 hours postdose ]
  • Plasma glucose concentrations [ Time Frame: Through 4 hours postdose ]
Not Provided
Not Provided
 
Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes
This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes (T2D) will be sufficiently safe and well tolerated to permit continued clinical investigation.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Type 2 Diabetes (T2D)
  • Drug: Omarigliptin
    Once-weekly 50 mg capsule
    Other Name: MK-3102
  • Drug: Placebo
    Once-weekly placebo capsule
  • Experimental: Healthy Omarigliptin
    Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
    Intervention: Drug: Omarigliptin
  • Placebo Comparator: Healthy Placebo
    Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
    Intervention: Drug: Placebo
  • Experimental: T2D Omarigliptin
    Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
    Intervention: Drug: Omarigliptin
  • Placebo Comparator: T2D Placebo
    Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).
    Intervention: Drug: Placebo
Addy C, Tatosian D, Glasgow XS, Gendrano IN 3rd, Kauh E, Martucci A, Johnson-Levonas AO, Selverian D, Matthews CZ, Gutierrez M, Wagner JA, Aubrey Stoch S. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus. Clin Ther. 2016 Mar;38(3):516-30. doi: 10.1016/j.clinthera.2015.12.020. Epub 2016 Feb 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
May 11, 2010
May 11, 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • obese (body mass index [BMI] ≥30 kg/m² and ≤40 kg/m²) male participants and female participants of non-childbearing potential
  • has been diagnosed with T2D (Panel B)
  • is not actively participating in a weight loss program

Exclusion Criteria:

  • has a history of clinically-significant disease (other than T2D)
  • has a history of cancer
  • has estimated creatinine clearance ≤60 mL/min
  • is unable to refrain from or anticipates the use of any prescription or non-prescription medication
  • consumes excessive amounts of alcohol or caffeine
  • has participated in a previous omarigliptin study
Sexes Eligible for Study: All
45 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT01088711
3102-004
No
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Director Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP